UPPSALA, Sweden, Oct. 6, 2026 /PRNewswire/ -- Beactica Therapeutics AB, a Swedish precision medicine company, today announced the selection of BEA-28 as a preclinical candidate for its TEAD programme, which is aimed at developing novel therapies for a range of aggressive,...
Hence then, the article about beactica therapeutics selects bea 28 as a preclinical candidate a first in class tead degrader for biomarker selected cancers was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Beactica Therapeutics selects BEA-28 as a preclinical candidate, a first-in-class TEAD degrader for biomarker-selected cancers )
Also on site :
- Martha Stewart’s Stylish Stoneware Food Container Set Is Perfect for Leftovers, and Just $25 Ahead of Prime Day
- ‘Riverdance’ & ‘Lord of the Dance’ Fans Shocked as Michael Flatley Shares His Wife’s Death at 52: What Happened?
- Neon Sets ‘Artificial’ Oscar Campaign With Andrew Garfield in Supporting Actor, Yura Borisov in Lead (EXCLUSIVE)